All In MedTech

Device Trial Radar · NCT03047239

TF for the Prediction of Visual Field Progression

A Prospective Study Investigating the Relationship Between SENSIMED Triggerfish® Ocular Dimensional Profiles and Disease Progression in Patients With Open Angle Glaucoma

Last checked: Nov 19, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jun 1, 2023

Primary completion

Jun 1, 2023

Study completion Jun 1, 2023

Sponsor

Lead sponsor
Sensimed AGNot on our public-company list
Sponsor type
Industry
First posted
Feb 8, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
No
Who can join
All sexes, from 22 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Baseline 24-hour SENSIMED Triggerfish (TF) recordings as well as functional and structural vision tests measured prospectively every 3 months over a 2-year period, will be used to model TF's ability to serve as a risk factor for individual progression rates.

Conditions

  • Open Angle Glaucoma

Interventions

  • SENSIMED TriggerfishDevice

    Smart contact lens based device indicated to detect the peak patterns of variation in intraocular pressure over a maximum period of 24 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Diagnostic odds ratio (DOR) for a SENSIMED Triggerfish based model for the prediction of visual field annual progression rate (24-2 SITA Standard) measured as Mean Deviation (MD) slopeTime frame: 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.